Haemonetics (HAE) Stock Overview
A medical technology company, provides a suite of hospital technologies solutions in the United States and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 2/6 |
| Past Performance | 5/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
HAE Community Fair Values
Create NarrativeSee what 9 others think this stock is worth. Follow their fair value or set your own to get alerts.
Haemonetics Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$54.54 |
| 52 Week High | US$94.99 |
| 52 Week Low | US$50.68 |
| Beta | 0.40 |
| 1 Month Change | -27.06% |
| 3 Month Change | -21.71% |
| 1 Year Change | -27.35% |
| 3 Year Change | -24.69% |
| 5 Year Change | -40.22% |
| Change since IPO | 818.57% |
Recent News & Updates
I'm Recommending Haemonetics Again, But With Caveats (Ratings Upgrade)
Aug 11Market Cool On Haemonetics Corporation's (NYSE:HAE) Earnings Pushing Shares 27% Lower
Aug 08
Recent updates
I'm Recommending Haemonetics Again, But With Caveats (Ratings Upgrade)
Aug 11Market Cool On Haemonetics Corporation's (NYSE:HAE) Earnings Pushing Shares 27% Lower
Aug 08Haemonetics (NYSE:HAE) Seems To Use Debt Quite Sensibly
Jun 30Market Participants Recognise Haemonetics Corporation's (NYSE:HAE) Earnings
Jun 10Do Haemonetics' (NYSE:HAE) Earnings Warrant Your Attention?
May 10Is Haemonetics (NYSE:HAE) Using Too Much Debt?
Mar 18Haemonetics: Almost Blood In The Streets
Feb 20Haemonetics (NYSE:HAE) Is Posting Promising Earnings But The Good News Doesn’t Stop There
Feb 13Investors Interested In Haemonetics Corporation's (NYSE:HAE) Earnings
Dec 06These 4 Measures Indicate That Haemonetics (NYSE:HAE) Is Using Debt Reasonably Well
Sep 09
Innovative Express Plus Technology And Strategic Market Expansion Set To Propel Revenue Growth
Innovation and R&D in Blood Management Technologies, including new products, are expected to increase market share and net margins through product differentiation.What You Can Learn From Haemonetics Corporation's (NYSE:HAE) P/E
Aug 14Are Investors Undervaluing Haemonetics Corporation (NYSE:HAE) By 46%?
Jul 18Haemonetics Undervalued As It Passes Into A Period Of Softer Reported Growth
Jun 21Does Haemonetics (NYSE:HAE) Deserve A Spot On Your Watchlist?
Apr 30Haemonetics Corporation's (NYSE:HAE) Share Price Matching Investor Opinion
Apr 12Haemonetics Corporation (NYSE:HAE) Shares Could Be 35% Below Their Intrinsic Value Estimate
Mar 07Haemonetics Corporation: Improved Performance, Another Bolt-On Deal
Mar 06The Strong Earnings Posted By Haemonetics (NYSE:HAE) Are A Good Indication Of The Strength Of The Business
Feb 15The Price Is Right For Haemonetics Corporation (NYSE:HAE)
Jan 01Haemonetics: Solid Performance Of This Blood Play
Nov 22Here's Why We Think Haemonetics (NYSE:HAE) Might Deserve Your Attention Today
Nov 14Is Haemonetics (NYSE:HAE) A Risky Investment?
Oct 24Haemonetics Offers Relatively Rare Momentum In A Tough Medical Device Environment
Oct 13Haemonetics' Fiscal Q1 2024: Blood, Sweat, And Stellar Gains
Aug 09Here's Why Haemonetics (NYSE:HAE) Has Caught The Eye Of Investors
Aug 09An Intrinsic Calculation For Haemonetics Corporation (NYSE:HAE) Suggests It's 48% Undervalued
Jul 25Haemonetics (NYSE:HAE) Has A Rock Solid Balance Sheet
Jul 07Haemonetics (NYSE:HAE) Has A Rock Solid Balance Sheet
Apr 06Is There An Opportunity With Haemonetics Corporation's (NYSE:HAE) 46% Undervaluation?
Mar 19Haemonetics Executing Well, But Valuation Dogged By Concerns About A Large Customer
Feb 16Haemonetics: Earnings Rate Of Change Justifies High Multiples
Feb 01We Think Haemonetics (NYSE:HAE) Can Manage Its Debt With Ease
Jan 05Is There An Opportunity With Haemonetics Corporation's (NYSE:HAE) 36% Undervaluation?
Dec 15Shareholder Returns
| HAE | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | -1.2% | 0.2% | 0.4% |
| 1Y | -27.3% | 3.3% | 15.7% |
Return vs Industry: HAE underperformed the US Medical Equipment industry which returned 3.3% over the past year.
Return vs Market: HAE underperformed the US Market which returned 15.7% over the past year.
Price Volatility
| HAE volatility | |
|---|---|
| HAE Average Weekly Movement | 8.4% |
| Medical Equipment Industry Average Movement | 8.1% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 17.2% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: HAE has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: HAE's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1971 | 3,023 | Chris Simon | www.haemonetics.com |
Haemonetics Corporation, a medical technology company, provides a suite of hospital technologies solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions, including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 tools. It also provides treatment in electrophysiology, critical care, neurocritical care, trauma, burn surgery, spine surgery, and cancer surgery; SavvyWire, a sensor-guided 3-in-1 guidewire for TAVR procedures; and OptoWire, a pressure guidewire that measures fractional flow reserve and diastolic pressure ratio, as well as fiber optic sensor solutions used in medical devices and other critical industrial applications.
Haemonetics Corporation Fundamentals Summary
| HAE fundamental statistics | |
|---|---|
| Market cap | US$2.63b |
| Earnings (TTM) | US$163.34m |
| Revenue (TTM) | US$1.35b |
Is HAE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| HAE income statement (TTM) | |
|---|---|
| Revenue | US$1.35b |
| Cost of Revenue | US$554.93m |
| Gross Profit | US$791.12m |
| Other Expenses | US$627.78m |
| Earnings | US$163.34m |
Last Reported Earnings
Jun 28, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 3.39 |
| Gross Margin | 58.77% |
| Net Profit Margin | 12.13% |
| Debt/Equity Ratio | 138.9% |
How did HAE perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/09/02 12:24 |
| End of Day Share Price | 2025/08/29 00:00 |
| Earnings | 2025/06/28 |
| Annual Earnings | 2025/03/29 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Haemonetics Corporation is covered by 28 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Daniel Owczarski | Avondale Partners |
| David Rescott | Baird |
| Gary Prestopino | Barrington Research Associates, Inc. |